Bethenny Frankel revealed that her chronic kidney disease diagnosis has moved into the next stage. “Just left the kidney doctor, he said I actually have stage 3A chronic kidney disease which is right ...
Aims Heart failure (HF) often coexists with chronic kidney disease (CKD), impacting prognosis. This study aims to evaluate ...
Atrasentan shows clinically meaningful effects on kidney function in IgA nephropathy patients, including those receiving SGLT2 inhibitors.
The ‘acidity myth’ is widely marketed; however, true systemic acidosis is rare in healthy individuals, and alkali therapy has limited evidence outside specific diseases.
GlobalData on MSN
Novartis reports final data of ALIGN trial in IgAN
A total of 340 biopsy-confirmed IgAN patients were randomised to daily oral Vanrafia or a placebo for approximately 132 weeks.
Verywell Health on MSN
5 stages of chronic kidney disease (CKD) from first symptoms to kidney failure
Medically reviewed by Robert Burakoff, MD Key Takeaways Stage 1 CKD often doesn't cause noticeable symptoms but requires ...
Heart disease, diabetes, and kidney disease are closely connected. They often develop from the same risk factors.
Stage 2 clear cell renal cell carcinoma is typically curable, especially when detected early. Surgery remains the cornerstone of treatment, with excellent outcomes in many cases. Patients are ...
Add Yahoo as a preferred source to see more of our stories on Google. ljubaphoto via Getty Images Your kidneys are pretty vital: They filter your blood and get rid of the waste in the body through ...
Early kidney damage is silent but preventable routine blood and urine tests catch it before symptoms.
Phase 3 trials showed Vanrafia slowed the decline in kidney function for adults with the progressive autoimmune kidney ...
Novartis to seek full FDA approval for IgAN drug Vanrafia despite missing ph. 3 kidney function goal
It’s déjà vu all over again. Just as the kidney disease space becomes increasingly competitive, Novartis has found itself intending to turn a statistical miss into a regulatory win. | It’s déjà vu all ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results